BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Moskowitz, 2012, Diffuse large B cell lymphoma: How can we cure more patients in 2012?, Best Pract Res Clin Haematol, 25, 41, 10.1016/j.beha.2012.01.008
Pileri, 2011, Lymphoma classification: The quiet after the storm, Semin Diagn Pathol, 28, 113, 10.1053/j.semdp.2011.02.001
Abid, 2005, Diffuse large B cell lymphoma (DLBCL) in Pakistan: An emerging epidemic?, Asian Pac J Cancer Prev, 6, 531
Song, 2015, Epstein-barr virus-positive diffuse large B-cell lymphoma in the elderly: A matched case-control analysis, PLoS One, 10, e0133973, 10.1371/journal.pone.0133973
Harris, 2000, Lymphoma classification-from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms, Ann Oncol, 11, S3, 10.1093/annonc/11.suppl_1.S3
Sehn, 2007, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, 109, 1857, 10.1182/blood-2006-08-038257
He, 2014, Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: Evidence from a systematic meta-analysis, BMC Cancer, 14, 153, 10.1186/1471-2407-14-153
Song, 2015, High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy, Int J Hematol, 101, 140, 10.1007/s12185-014-1719-3
Li, 2012, High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy, Eur J Haematol, 88, 510, 10.1111/j.1600-0609.2012.01778.x
Hasselblom, 2008, Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma, Leuk Lymphoma, 49, 1501, 10.1080/10428190802140055
Jerkeman, 2004, Nordic Lymphoma Group study: Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study, Ann Hematol, 83, 414, 10.1007/s00277-004-0855-x
Ali, 2012, A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer, J Pathol, 226, 97, 10.1002/path.2976
Iqbal, 2011, BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab, Clin Cancer Res, 17, 7785, 10.1158/1078-0432.CCR-11-0267
Iqbal, 2006, BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma, J Clin Oncol, 24, 961, 10.1200/JCO.2005.03.4264
Pfreundschuh, 2008, Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study, Lancet Oncol, 9, 435, 10.1016/S1470-2045(08)70078-0
Hans, 2004, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, 103, 275, 10.1182/blood-2003-05-1545
Hu, 2013, MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program, Blood, 121, 4021, 10.1182/blood-2012-10-460063
Johnson, 2012, Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, 30, 3452, 10.1200/JCO.2011.41.0985
Green, 2012, Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, 30, 3460, 10.1200/JCO.2011.41.4342
Mationg-Kalaw, 2012, Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?, Histopathology, 61, 1214, 10.1111/j.1365-2559.2012.04351.x
Akyurek, 2012, Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab, Cancer, 118, 4173, 10.1002/cncr.27396
Wilson, 2007, CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma, Leuk Lymphoma, 48, 1102, 10.1080/10428190701344881
Mounier, 2003, Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL), Blood, 101, 4279, 10.1182/blood-2002-11-3442
Montraveta, 2015, Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199, Oncotarget, 6, 21159, 10.18632/oncotarget.4230
Cervantes-Gomez, 2015, Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic Leukemia, Clin Cancer Res, 21, 3705, 10.1158/1078-0432.CCR-14-2809
Klanova, 2016, Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-Dependent subgroups of diffuse large B-cell lymphoma, Clin Cancer Res, 22, 1138, 10.1158/1078-0432.CCR-15-1191